Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Journal of Dermatological Treatment

Volumn 24, Issue 5, 2013, Pages 369-373

  Bonafede, Machaon ^a   Johnson, Barbara H ^a   Fox, Kathleen M ^b   Watson, Crystal ^c   Gandra, Shravanthi R ^c  

^a IBM WATSON HEALTH   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

Discontinue; Psoriasis; Psoriatic arthritis; Restart; Switch; TNF inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883590178     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.755255     Document Type: Article

References (19)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361: 496-509
3. Dhir V, Aggarwal A. Psoriatic arthritis: A critical review. Clin Rev Allergy Immunol. 2012; DOI:10.1007/s12016-012-8302-6
4. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64: Ii14-ii17
5. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: A unified concept twenty years on. Arthritis Rheum. 1999;42:1080-1086
6. Mease PJ. Psoriatic arthritis: Update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70:i77-i84
7. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10-15
8. Ko JM, Qureshi AW. Skin and bone: The pathogenetic relationship between psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2010;145:393-406
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-174
10. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70:i2-i36
11. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. Immunotherapy. 2010;2:817-833
12. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17- signaling, not "immediate response" TNF genes. J Allergy Clin Immunol. 2009;124:1022-1010.e1-395
13. Tan JK, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc. 2007;12:38-45
14. Enbrel® (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation, 2011
15. Humira- (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories, 2011
16. Thayer S, Watson C, Song R, et al. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13:228-235
17. Chastek B, Fox KM, Watson C, et al. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24:25-33
18. Chastek B, Fox KM, Watson C, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012;29:691-697
19. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52